Prognosis and outcome of patients with acute myeloid leukemia based on mutation with or without additional abnormal cytogenetics.

The FMS-like tyrosine kinase 3-internal tandem duplication () gene mutation is present in ~20% of patients with acute myeloid leukemia (AML). Patients with an mutation have a poor prognosis. However, the prognostic function of combined with other cytogenetic abnormalities are not clear.

Long-term effect of all-trans retinoic acid and arsenic trioxide sequential maintenance in patients with acute promyelocytic leukemia.

The specific prognostic factors and the long-term effects of different treatment options in APL remain unclear. In this retrospective study, 70 APL patients were treated with ATRA + DNR/DA or ATRA + ATO regimens for induction therapy and DA or ATRA + ATO for consolidation and maintenance therapy. The prognostic factors and treatment effects on outcome were analyzed.